Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
49 results about "Polymannuronic acid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Polymannuronate hydrolase (EC 3.2.1.121, polymannuronic acid polymerase) is an enzyme with systematic name poly(mannuronide) mannuronohydrolase. This enzyme catalyses ...
Novel alginate lyase, preparation method and application thereof
ActiveCN109295043AHigh activityStrong toleranceFermentationVector-based foreign material introductionPolymannuronic acidEscherichia coli
The invention discloses an alginate lyase (Alg509) derived from marine bacteria and a gene thereof, and also disclosed a method for recombinant expression and preparation of the alginate lyase. According to the method, the alg509 gene is cloned into an E. coli expression vector, and the vector is transformed into an E. coli host strain to obtain a recombinant engineering strain which can heterologously express the enzyme. The alginate lyase Alg509 disclosed in the invention has high enzyme activity, the specific enzyme activity can reach up to 48000 U / mg and above, the optimum reaction pH is 10, the optimum reaction temperature is 55 DEG C, and the enzyme activity has no dependence on various metal ions. The enzyme is active to sodium alginate, poly-guluronic acid (polyG) and ploymannuronic acid (polyM), and can completely degrade sodium alginate to produce alginate oligomers such as alginate disaccharide, alginate trisaccharide, alginate tetrasccharide, etc. The enzyme exhibits strongbasophilia, has certain tolerance to high pH, has certain potential of industrial applications, and can be widely applied in the fields of agriculture, food, feed additive, medicine and the like.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Sodium alginate catenase gene algl and its preparation method and application
InactiveCN1514000AIncrease temperatureImprove stabilityBacteriaGenetic engineeringPolymannuronic acidEscherichia coli
An algin lyase gene algl able to code marine pseudomonads QDA is prepared from the QDA genome DNA library by cloning, and cna be used to prepare the recombinant algin lyase. It can degradate the homopolymannuronic acid to obtain algin oligose. Said recombinant algin lyase features high stability of temp and pH value, and activity, high expression level in colibacillus 24%, and low cost.
Owner:OCEAN UNIV OF CHINA
Application of mannan-oligosaccharide aldehyde acid salt in preparing medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis
ActiveCN103961365AImprove protectionAbundant resourcesOrganic active ingredientsDigestive systemPolymannuronic acidMagnesium salt
The invention belongs to the field of marine drugs and particularly relates to the application of mannan-oligosaccharide aldehyde acid salt in preparing a medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis. The mannan-oligosaccharide aldehyde acid salt is used for preparing the medicine for protecting livers and curing various hepatitis, liver fibrosis or cirrhosis. The mannan-oligosaccharide aldehyde acid salt takes algin as a raw material, through a chemical degradation method or a physical degradation method, or the combination of the two degradation methods, mannan-oligosaccharide aldehyde acid with different molecular weights can be obtained; the mannan-oligosaccharide aldehyde acid is prepared through neutralization into lithium salt, sodium salt, kali salt, calcium salt or magnesium salt of the mannan-oligosaccharide aldehyde acid with different molecular weights, the molecular skeleton of the mannan-oligosaccharide aldehyde acid adopts a linear oligosaccharide compound formed by connecting D-mannuronic acid (M) through a Beta-1, 4 glucosidic bond. The product in the invention is derived from algal polysaccharides, has the advantages of rich resources, easiness in industrialization, safety, effectiveness and the like, and has a wide development and application prospect in preventing and curing liver damage, and various hepatitis, liver fibrosis and cirrhosis.
Owner:MARINE BIOMEDICAL RES INST OF QINGDAO CO LTD
Application of poly mannuronic acid propyl ester sulfate in preparing anti- H1N1 influenza A virus medication
InactiveCN102743409AAvoid infectionPrevent proliferationOrganic active ingredientsAntiviralsCanine kidneyPolymannuronic acid
The invention provides applications of poly mannuronic acid propyl ester sulfate (PMS) in preparing anti- H1N1 influenza A virus medication. Experiments of the invention prove that PMS not only has great inhibition effect on the neuraminidase of the influenza A virus, but also has relatively good protection effect on canine kidney epithelial cells infected with the H1N1 influenza A virus, and can reduce the replication of the H1N1 virus with an effect that equal to the positive control medication ribavirin. Additionally, the PMS can effectively reduce the death rate of mice infected with the H1N1 influenza A virus and the survival time of the mice are prolonged. The poly mannuronic acid propyl ester sulfate provided by the invention has significant activity of inhibiting the neuraminidase of the H1N1 influenza A virus, and is proved to have good anti- H1N1 influenza A virus activity both in vivo and in vitro experiments, which shows the wide application prospect of the poly mannuronic acid propyl ester sulfate in preparing anti-H1N1 influenza A virus medication.
Owner:OCEAN UNIV OF CHINA
Application of mannuronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury
ActiveCN103446174AAchieve protectionImprove antioxidant capacityOrganic active ingredientsDigestive systemPolymannuronic acidDietary supplement
The invention provides application of mannuronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury. Mannuronic acid oligomers with different molecular weights, which are obtained by degrading polymannuronic acid graded and purified from algin, can lower the hepatosomatic index increase caused by alcoholic injury, resist triglyceride and cholesterol increase caused by alcohol, effectively lower glutamic-pyruvic transaminase and glutamic oxaloacetic transaminase increase in serum caused by alcohol, enhance the total oxidation resistance and glutathione level of the serum, lower the mouse drunkenness rate, prolong the mouse drunkenness time, and shorten the sober-up time, thereby implementing the protective action and hangover alleviating function on alcoholic hepatic injury. The products provided by the invention are derived from marine natural products, have the advantages of abundant resources, high industrialization tendency, high safety, high effectiveness and the like, and have wide development and application prospects in the aspects of prevention and treatment of alcoholic hepatic injury, hangover alleviation and liver protection.
Owner:OCEAN UNIV OF CHINA
Method for preparing alginate oligosaccharide monomers by using microwave radiation
ActiveCN103059163AImprove solubilityIncrease productionSaccharides productionPolymannuronic acidChemical industry
The invention provides a method for preparing alginate oligosaccharide monomers by using microwave radiation. The method comprises the following steps of: preparing polymannuronic acid or polyguluronic acid in algin, subjected to graded purification, into solutions or suspensions with different concentrations; performing microwave radiation in a microwave reaction system for degradation for 5 to 30 minutes; then cooling, filtering and freeze-drying the degradation product to obtain an oligosaccharide mixture; and separating and purifying the oligosaccharide mixture by using a gel column chromatography to obtain oligosaccharide monomers with different polymerization degrees. The method has the advantages that the degradation efficiency is high, the yield of oligosaccharide is high, acid or a buffer salt is not added during the degradation, few byproducts are generated, the after-treatment is simple and convenient, the product is easy to separate and purify, clean and environment-friendly effects are achieved, the cost is low, oligosaccharide mixtures with different molecular weight distributions and oligosaccharide monomers with different polymerization degrees can be prepared according to different aims and purposes, and the product is applied to various fields of foods, medicaments, chemical industry and the like.
Owner:OCEAN UNIV OF CHINA
Oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicines
ActiveCN102920729AIncrease the number ofPromote formationOrganic active ingredientsBlood disorderPolymannuronic acidBone Marrow Stromal Cell
The invention provides oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicine. In in-vitro cell experiments, oligomerization mannuronic acid can obviously promote forming of colony-forming unit-granulocyte macrophage (CFU-GM), simultaneously can promote marrow stroma cells to breed and secrete CFU-GM and promote splenic lymphocytes to secrete interleukin-3. In vivo experiments further indicates that oligomerization mannuronic acid can obviously restrain reduction of white blood cells in mice caused by cyclophosphamide, increase the number marrow nucleated cell of the mice and promote forming of CFU-GM. Experiment results indicate that oligomerization mannuronic acid can be developed to be a clinical medicine capable of effectively preventing leucopenia.
Owner:MARINE BIOMEDICAL RES INST OF QINGDAO CO LTD
Marine oligosaccharide compound with type II diabetes resisting activity
ActiveCN101649004AGood anti-type II diabetes activityImprove securityOrganic active ingredientsSugar derivativesPolymannuronic acidCarboxyl radical
The invention relates to a marine oligosaccharide compound with type II diabetes resisting activity, which is a compound which is formed by following steps: taking D-polymannose aldehydic oligosaccharide which comes from sea and contains carboxyl in each oligosaccharide ring, reacting with dilute alkali and chromium salt solution and introducing trivalent chromium ions which is closely relative tothe generation and the development of diabetes into oligosaccharide molecules. A pharmacological experiment proves that the product has remarkable effect on accelerating insulin secretion, is not influenced by amylin and has effects on lightening glucose load, improving blood-lipoid metabolism, insulin sensitivity and certain kidney protection and lightening pancreatic injury for type II diabetesrats and mouse. The product of the invention comes from marine natural species, has the advantages of good security, unique structure, low molecular weight, high chromium binding ratio, good oral absorption effect, and the like, can play a hypoglycemic role in a plurality of links and has favorable market application prospect on the aspect of preventing and treating type II diabetes.
Owner:OCEAN UNIV OF CHINA
Application of oligomeric mannuronic acid to preparation of medicine for resisting influenza A virus subtype H1N1
InactiveCN102488697ASmall molecular weightImprove solubilityOrganic active ingredientsAntiviralsMadin Darby canine kidney cellPositive control
The invention provides application of oligomeric mannuronic acid to preparation of a medicine for resisting influenza A virus subtype H1N1. Through experiment, the oligomeric mannuronic acid (OM) has a good function of protecting madin-darby canine kidney cells which are infected by influenza A virus subtype H1N1 in vitro, can effectively reduce virus reproduction, and has an effect equal to thatof a positive control medicine ribavirin. Moreover, OM can also reduce the death of mice which is caused by infection of influenza A virus subtype H1N1 obviously, and prolong the survival time. The oligomeric mannuronic acid (OM) has the advantages of high water solubility and stability, and safety and low toxicity and the like; and in an in vivo-in vitro experiment, the OM can resist influenza Avirus subtype H1N1 well, and the oligomeric mannuronic acid can be expected to be developed to the medicine for resisting influenza A virus.
Owner:OCEAN UNIV OF CHINA
Method for preparing algin lyase and its application
InactiveCN1445365AShort lifeIncrease vitalityBacteriaPeptide/protein ingredientsPolymannuronic acidLyase
A process for preparing algin lyase includes such steps as preparing culture medium, sterilizing, cooling, inoculating Vibro sp QY101, shake fermenting culture at constant temp. removing bacteria from fermented liquid, ultrafiltering supernatant and concentrating. Its advantages are short fermenting time, high output and activity and high temp stability. It can be used to prepare alginic oligose.
Owner:OCEAN UNIV OF CHINA
Conjugate of polymer and biological stain and preparation method and application thereof
InactiveCN102504603AGood water solubilityLong developing timeOrganic dyesIn-vivo testing preparationsPolymannuronic acidLymphatic vessel
The invention provides a conjugate of a polymer and a biological stain and a preparation method and application of the conjugate. The conjugate has the formula G-X-B, wherein the polymer G is selected from the group consisting of glucans, fructosans, polymannuronic acid, polyguluronic acid, heteropolysaccharides, mono- or hetero-polysaccharides, mono- or hetero-polyuronic acid polysaccharides, mono- or hetero-polyuronic acid sulfate esters, hydrophilic alcohol high polymers, polylysine, polyglutamic acid and polyaspartic acid; the linking group X is a C1-C10 organic group; and the biological stain or a derivative B thereof may be toluidine blue, methylene blue, Evans blue, neutral red, Janus green or bright cresol purple. The conjugate can stain bilateral neck and submaxillary or submental lymphatic vessels and lymph nodes in New Zealand white rabbits by indirect lymph staining method, without diffusion in tongue body. No obvious toxic and adverse effects appear in all experimental animals in each group, and no obvious pathological changes appear in histological examination of internal organs.
Owner:OCEAN UNIV OF CHINA
Incision difunctional alginate lyase Aly2 generating various monosaccharide products, encoding gene of Aly2 and application of Aly2
ActiveCN108048435AStable physical and chemical propertiesHigh degradation activityGenetic engineeringFermentationPolymannuronic acidNucleotide
The invention relates to incision difunctional alginate lyase Aly2 generating various monosaccharide products, an encoding gene of the Aly2 and an application of the Aly2. The amino acid sequence of the Aly2 is as shown in SEQ ID NO. 2, and the nucleotide sequence of the encoded Aly2 is as shown in SEQ ID NO. 1. The specific activity of prepared gene engineering recombinant protein rAly2 for alginate, polyguluronic acid and polymannuronic acid is 2025U / mg, 3672U / mg and 1324U / mg, so that the gene engineering recombinant protein rAly2 is a difunctional enzyme. The enzyme is an incision enzyme, and final main products are unsaturated disaccharide and unsaturated trisaccharide when an alginate polysaccharide substrate is thoroughly degraded. When different oligosaccharide substrates are degraded, various monosaccharide products such as saturated M and G or unsaturated delta can be generated. Besides, the rAly2 is stable in biochemical property, is a potential tool enzyme, can be applied tothe field of medicines, food and the like and has a wide application prospect.
Owner:SHANDONG UNIV
Method for preparing selenylation poly mannuronic acid and application of selenylation poly mannuronic acid
ActiveCN102936291ALow costHigh yieldOrganic active ingredientsNervous disorderDiseasePolymannuronic acid
The invention relates to the technical field of selenylation polysaccharide and provides a method for preparing selenylation poly mannuronic acid. The method comprises steps of suspending poly mannuronic acid in an anhydrous organic solvent; adding a sulfur trioxide-pyridine compound dissolved by the anhydrous organic solvent with stirring; conducting reaction for 1-10 hours at the constant temperature from 20 DEG C to 100 DEG C; adding ethanol; centrifugalizing a reaction product; cleaning by using the ethanol; adding water and dissolving; adjusting the Potential of Hydrogen (PH) value to the neuter by using alkali; conducting dialysis; conducting filtering; conducting freezing and drying; obtaining sulfonated poly mannuronic acid; subjecting the sulfonated poly mannuronic acid and selenite to the reaction in the acid solution at the catalysis of Ba2+; adding sulphate; extracting supernatant fluid through centrifugation; adjusting the Potential of Hydrogen (PH) value to the neuter by using the alkali; conducting dialysis; conducting filtering; conducting freezing and drying; and obtaining the selenylation poly mannuronic acid. The invention also provides application of the selenylation poly mannuronic acid which is prepared through the method in medicines and health products for prevention and curing of Alzheimer's disease.
Owner:SHENZHEN UNIV
Alginate lyase SHA-3 gene and prokaryotic expression vector thereof
ActiveCN104878030ABroad substrate specificityGood yieldFermentationVector-based foreign material introductionPolymannuronic acidNucleotide
The invention discloses an alginate lyase SHA-3 gene with a nucleotide sequence as shown in SEQ ID NO:1. The invention establishes a prokaryotic expression vector of the alginate lyase SHA-3 gene. The vector can obtain an expression product, namely alginate lyase SHA-3 within relatively-short time, has wide substrate specificity, can take polymannuronic acid PolyM or polyguluronic acid PolyG as a substrate, and has the enzyme activity of 12U / mg so as to be a difunctional enzyme with a wide application prospect. The prokaryotic expression vector and a whole expression system are easily operated and are conveniently used for realizing industrial production.
Owner:KUNMING UNIV OF SCI & TECH
Antithrombotic medicament for intravenous injection and preparation method and application thereof
ActiveCN102212148AReduce the degree of polymerizationHigh purityOrganic active ingredientsFermentationPolymannuronic acidAntithrombotic Agent
The invention provides an antithrombotic medicament for intravenous injection. The medicament is a modified acidic polysaccharide consisting of only one monosaccharide and has a structural general formula, wherein R is -CH3 or -CH2-CH(OH)-CH3; R' is -H or -SO3Na; each sugar ring has at least one R' which is -SO3Na; n is equal to 2 to 6; when R is -CH3, the compound represented by the structural general formula is an oligomannuronicacid methyl acetate sulfate sodium salt; and when R is -CH2-CH(OH)-CH3, the compound represented by the structural general formula is an oligomannuronicacid proply acetate sulfate sodium salt. The medicament for intravenous injection has obvious anticoagulation, wherein the anticoagulation titer is 17 to 23; rabbit collagen induced platelet aggregation and platelet adhesion are obviously inhibited; and local ischemic brain damage caused by formation of cerebral thrombosis is lessened by inhibiting the formation of cerebral thrombosis and ischemic brain tissues are obviously protected.
Owner:OCEAN UNIV OF CHINA
Application of poly mannuronic acid propyl ester sulfate in preparing anti- H1N1 influenza A virus medication
InactiveCN102743409BAvoid infectionPrevent proliferationOrganic active ingredientsAntiviralsCanine kidneyPolymannuronic acid
The invention provides applications of poly mannuronic acid propyl ester sulfate (PMS) in preparing anti- H1N1 influenza A virus medication. Experiments of the invention prove that PMS not only has great inhibition effect on the neuraminidase of the influenza A virus, but also has relatively good protection effect on canine kidney epithelial cells infected with the H1N1 influenza A virus, and can reduce the replication of the H1N1 virus with an effect that equal to the positive control medication ribavirin. Additionally, the PMS can effectively reduce the death rate of mice infected with the H1N1 influenza A virus and the survival time of the mice are prolonged. The poly mannuronic acid propyl ester sulfate provided by the invention has significant activity of inhibiting the neuraminidase of the H1N1 influenza A virus, and is proved to have good anti- H1N1 influenza A virus activity both in vivo and in vitro experiments, which shows the wide application prospect of the poly mannuronic acid propyl ester sulfate in preparing anti-H1N1 influenza A virus medication.
Owner:OCEAN UNIV OF CHINA
Alginic acid lyase SHA-5 gene and prokaryotic expression vector thereof
ActiveCN105255922ABroad substrate specificityEasy to operateFermentationVector-based foreign material introductionPolymannuronic acidNucleotide
The invention discloses an alginic acid lyase SHA-5 gene. The nucleotide sequence of the alginic acid lyase SHA-5 gene is shown as SEQ ID NO:1. A prokaryotic expression vector of the alginic acid lyase SHA-5 gene is structured, the expression product alginic acid lyase SHA-5 can be obtained in a short time through the vector, and the vector has wide substrate specificity; both polymannuronic acid PolyM and polyguluronic acid PolyG can be used as a substrate, the enzyme activity reaches 17 U / mg, and the alginic acid lyase SHA-5 is difunctional and has wide application prospects. The prokaryotic expression vector and an integral expression system are easy to operate, and industrial production is convenient.
Owner:KUNMING UNIV OF SCI & TECH
Endo-alginate lyase and coding gene and application thereof
The invention discloses endo-alginate lyase and a coding gene and application thereof. A primer is designed and synthesized by taking genome DNA of a Vibriosp.MCCC 1A13243 as a template, an endo-alginate lyase gene is amplified through PCR, the gene is cloned into a pET-22b expression vector, induced expression is carried out in escherichia coli E.coli BL21, and affinity chromatography purification is carried out by adopting Ni-Sepharose to obtain the recombinant endo-alginate lyase protein with higher purity. The optimum temperature of the enzyme is 35 DEG C, the optimum pH of the enzyme is 8.5, and the enzyme has good stability in the ranges of 0-65 DEG C and pH 4.5-10.5; co<2+>, Cu<2+>, Mn<2+> and Fe<3+> can obviously promote the enzyme activity; and the enzyme has the highest degradation effect on sodium alginate and can further degrade polyguluronic acid and polymannuronic acid, and a main product for degrading the three substrates is disaccharide. The endo-alginate lyase has advantages in the aspect of producing alginate oligosaccharide, especially brown algae disaccharide.
Owner:THIRD INST OF OCEANOGRAPHY MINIST OF NATURAL RESOURCES
Vaccines absorbable by the transmucosal way
InactiveUS20030049279A1Easy to manageBiocideVertebrate antigen ingredientsAntigenPolymannuronic acid
The main object of the present invention is to provide polysaccharide-coated antigens derivatized with lectins for pharmaceutical use. In said vaccines, polysaccharides are preferably selected from the group consisting of chitosan, low-molecular-weight and high-deacetylation-degree chitosan, methyl glycol chitosan, alginic acid, polymannuronic acid and salts or derivatives thereof. In the vaccines of the invention, antigens are microorganisms, infectious agents or constituents thereof, hormones, enzymes, proenzymes, narcotics, bioactive peptides, metabolites, biological precursors, cell constituents, allergens, and the lectins are of vegetable origin.
Owner:GRISOTECH
Application of oligomannuronic acid in the preparation of drugs, health products or dietary supplements for preventing and treating alcoholic liver injury
ActiveCN103446174BAchieve protectionImprove antioxidant capacityOrganic active ingredientsDigestive systemPolymannuronic acidDietary supplement
The invention provides application of mannuronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury. Mannuronic acid oligomers with different molecular weights, which are obtained by degrading polymannuronic acid graded and purified from algin, can lower the hepatosomatic index increase caused by alcoholic injury, resist triglyceride and cholesterol increase caused by alcohol, effectively lower glutamic-pyruvic transaminase and glutamic oxaloacetic transaminase increase in serum caused by alcohol, enhance the total oxidation resistance and glutathione level of the serum, lower the mouse drunkenness rate, prolong the mouse drunkenness time, and shorten the sober-up time, thereby implementing the protective action and hangover alleviating function on alcoholic hepatic injury. The products provided by the invention are derived from marine natural products, have the advantages of abundant resources, high industrialization tendency, high safety, high effectiveness and the like, and have wide development and application prospects in the aspects of prevention and treatment of alcoholic hepatic injury, hangover alleviation and liver protection.
Owner:OCEAN UNIV OF CHINA
Novel alginate lyase BY17PV7 and application thereof
The invention relates to novel alginate lyase BY17PV7 and application thereof. The alginate lyase BY17PV7 is derived from Microbulbifer sp.BY17, the amino acid sequence of the alginate lyase BY17PV7 is shown as SEQ ID NO.1, and the nucleotide sequence of the coding gene by17pv7 is shown as SEQ ID NO. 2. The enzyme activity of the recombinant alginate lyase BY17PV7 can reach 124.7 U / mg, the optimum reaction temperature is 43 DEG C, the optimum reaction pH is 8.9, the alginate lyase BY17PV7 is kept relatively stable under the conditions of 20-40 DEG C and pH of 7.0-8.9, the alginate lyase BY17PV7 has degradation activity on sodium alginate, polymannuronic acid and polyguluronic acid, alginate oligosaccharides generated by enzymolysis are trisaccharide and tetrasaccharide, and the alginate lyase BY17PV7 has antioxidant activity. The alginate lyase BY17PV7 can be applied to the fields of alginate oligosaccharide production and industry, food, medicine and the like.
Owner:FUZHOU UNIV
Marine oligosaccharide compound with type II diabetes resisting activity and preparation method thereof
ActiveCN101649004BGood anti-type II diabetes activityImprove securityOrganic active ingredientsSugar derivativesPolymannuronic acidBinding ratio
The invention relates to a marine oligosaccharide compound with type II diabetes resisting activity, which is a compound which is formed by following steps: taking D-polymannose aldehydic oligosaccharide which comes from sea and contains carboxyl in each oligosaccharide ring, reacting with dilute alkali and chromium salt solution and introducing trivalent chromium ions which is closely relative to the generation and the development of diabetes into oligosaccharide molecules. A pharmacological experiment proves that the product has remarkable effect on accelerating insulin secretion, is not influenced by amylin and has effects on lightening glucose load, improving blood-lipoid metabolism, insulin sensitivity and certain kidney protection and lightening pancreatic injury for type II diabetes rats and mouse. The product of the invention comes from marine natural species, has the advantages of good security, unique structure, low molecular weight, high chromium binding ratio, good oral absorption effect, and the like, can play a hypoglycemic role in a plurality of links and has favorable market application prospect on the aspect of preventing and treating type II diabetes.
Owner:OCEAN UNIV OF CHINA
Application of oligomeric mannuronic acid salts in preparation of drugs and functional foods for delaying skin aging and regulating immunity/resisting inflammation
PendingCN112807322AHigh expressionAnti agingOrganic active ingredientsCosmetic preparationsPolymannuronic acidUronic acid
The invention provides application of oligomeric mannuronic acid salts in preparation of drugs and functional foods for delaying skin aging and regulating immunity / resisting inflammation. According to the invention, the oligomeric mannuronic acid salts with different molecular weights are prepared by using algin as a raw material and obtained by using a chemical degradation method or a physical degradation method or a combination of the two degradation methods; and oligomeric mannuronic acid is neutralized to prepare the oligomeric mannuronic acid salts with different molecular weights, and molecular skeletons of the oligomeric mannuronic acid salts are linear oligosaccharide compounds formed by D-mannuronic acid (M) through linking of beta-1, 4 glucosidic bonds. The product disclosed by the invention is derived from algal polysaccharides, has the advantages of being abundant in resources, prone to industrialization, safe, effective, etc., and has a wide development and application prospect in the aspect of preparing drugs and functional foods for delaying skin aging and regulating immunity.
Owner:OCEAN UNIV OF CHINA
Recombinant alginate lyase AlyL7 and application thereof
PendingCN114231514AHigh specific vitalityOvercome the shortcomings of low catalytic efficiencyFermentationVector-based foreign material introductionPolymannuronic acidNucleotide
The invention relates to a recombinant alginate lyase AlyL7 and application thereof. The amino acid sequence of the alginate lyase is shown as SEQ ID NO.1, and the nucleotide sequence of a coding gene of the alginate lyase is shown as SEQ ID NO.2. The recombinant alginate lyase belongs to bifunctional alginate lyase, the optimum reaction temperature of the recombinant alginate lyase is 40 DEG C, the optimum reaction pH of the recombinant alginate lyase is 9.0, the recombinant alginate lyase is stable under the conditions that the temperature is 0-25 DEG C and the pH is 5.0-10.0, and the recombinant alginate lyase has degradation activity on sodium alginate, polyguluronic acid and polymannuronic acid. The recombinant alginate lyase also belongs to an incision enzyme, and a final product obtained by enzymolysis of sodium alginate by the recombinant alginate lyase comprises unsaturated 1-5 sugars and mainly comprises unsaturated 2-3 sugars. The alginate lyase is high in reaction speed and high in efficiency, and has good industrial application potential.
Owner:FUZHOU UNIV
A kind of alginate lyase sha-3 gene and its prokaryotic expression vector
ActiveCN104878030BBroad substrate specificityEasy to operateFermentationVector-based foreign material introductionPolymannuronic acidNucleotide
Owner:KUNMING UNIV OF SCI & TECH
A method for preparing mannuronic acid monomers by degrading polymannuronic acid with sulfuric acid
Owner:QINGDAO BZ OLIGO BIOTECH
Antithrombotic medicament for intravenous injection and preparation method and application thereof
ActiveCN102212148BInhibit aggregationAvoid stickingSugar derivativesSaccharide compounds with non-saccharide radicalsAntithrombotic AgentPolymannuronic acid
Owner:OCEAN UNIV OF CHINA
Method for preparing oligomeric mannuronic diacid
ActiveUS10927137B2High reaction yieldQuick responseSugar derivativesSaccharide compounds with non-saccharide radicalsPolymannuronic acidContinuous reactor
The invention relates to a new method of preparing oligomannuronic diacids, important bioactives. The method utilizes oligomannuronic acids as starting materials and the target substances are obtained by acid degradation and active hypobromous acid oxidation steps. The method of preparing oligomannuronic diacids according to the invention employs moderate reaction conditions, has few side reactions, does not need further purification, achieves a yield of more than 90%, or even more than 95%, and is suitable for production with an on-line continuous reactor device, with reaction processes easy to implement automatic control.
Owner:SHANGHAI GREEN VALLEY PHARMA
Polymannuronic acid sulfate
A polymannuronic acid sulfate with anti-AIDS activity contains the primary molecular skeletons: the mannuronic acid linked with beta-D (1-4) and the guluronic acid linked with beta-L (1-4). The SO3Na is introduced to the hydroxy position on C2 and C3 of carbon ring. Its preparing process includes dewatering sodium alginate, dissolving, centrifugal separation, classifying with alcohol, dissolving the classified and degradated alginic acid, neutralizing with alkali, separating out solid, dewatering with alcohol, sulforating with chlorosulfonic acid, neutralizing with alkali, dewatering with alcohol and drying. It can be used to prepare anti-AIDS medicines.
Owner:OCEAN UNIV OF CHINA
A kind of alginate lyase, its preparation method and application
ActiveCN109295043BHigh activityNo dependencyFermentationVector-based foreign material introductionPolymannuronic acidLyase
The invention discloses a alginate lyase (Alg509) derived from marine bacteria and its gene. At the same time, the method for recombinant expression and preparation of the alginate lyase is also disclosed, which is about to alg509 The gene is cloned into an Escherichia coli expression vector, and the vector is transformed into an Escherichia coli host bacterium to obtain a recombinant engineering strain capable of heterologously expressing the enzyme. The alginate lyase Alg509 disclosed by the present invention has high enzyme activity, the specific enzyme activity can reach more than 48000U / mg, the optimum reaction pH is 10, the optimum reaction temperature is 55°C, and the enzyme activity has no dependence on various metal ions . The enzyme is active on sodium alginate, polyguluronic acid (polyG) and polymannuronic acid (polyM), and can completely degrade sodium alginate to produce fucobiose, fucoidanose, and fucoidan Sugar and other fucoidan oligosaccharides. The enzyme exhibits strong basophilicity, has a certain tolerance to high pH, has a certain potential for industrial application, and can be widely used in agriculture, food, feed additives, medicine and other fields.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com